Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCR-STAT3 in Adults With Refractory Solid Tumors
NCT06098651Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2023
- Primary completion
- Sep 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DCR-STAT3 in solid tumor and non-Hodgkin lymphoma (NHL), sponsored by Novo Nordisk. Primary endpoints: Incidence of adverse events and dose limiting toxicities at 8 weeks and Severity of adverse events at 8 weeks. Started Aug 2023; status: completed.
02
Drugs
DCR-STAT3
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06098651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06098651.